COVID-19: impact of vaccination in myeloma patients

por Hoornaert, E., Dachy, F., Hansenne, A., Bailly, S., van Maanen, A., Gruson, D., Vekemans, M-C.
Publicado 2022

P12: TREATMENTS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: RETROSPECTIVE CHART REVIEW OF REAL-WORLD OUTCOMES FOR STANDARD OF CARE

por Vekemans, M-C, Delforge, M, Anguille, S, Depaus, J, Meuleman, N, Van de Velde, A, Vande Broek, I, Strens, D, Van Hoorenbeeck, S, Moorkens, EJ, Diels, J, Ghilotti, F, Dalhuisen, S, Vandervennet, S
Publicado 2022

P906: IXAZOMIB, DARATUMUMAB AND LOW DOSE DEXAMETHASONE IN FRAIL PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): RESULTS OF THE MAINTENANCE TREATMENT OF THE PHASE II HOVON 14...

por Groen, K., Seefat, M., Nasserinejad, K., Stege, C. A., van der Spek, E., Bilgin, Y. M., Kentos, A., Sohne, M., van Kampen, R. J., Ludwig, I., Thielen, N., Durdu-Rayman, N., de Graauw, N. C., van de Donk, N. W., de Waal, E. G., Vekemans, M.-C., Timmers, G. J., van der Klift, M., Soechit, S., Geerts, P. A., Silbermann, M. H., Oosterveld, M., Nijhof, I., Sonneveld, P., Klein, S. K., Levin, M.-D., Zweegman, S.
Publicado 2022